Abstract
An increasing number of recombinant-DNA-derived pharmaceuticals appear to be antigenic, and antibody formation has been shown to have a clinical effect. To study these effects, standardization of the antibody assays is essential. A contributing factor to the antigenicity of recombinant DNA pharmaceuticals may be their formulation.
| Original language | English |
|---|---|
| Pages (from-to) | 37-42 |
| Number of pages | 6 |
| Journal | Pharmaceutical Sciences |
| Volume | 3 |
| Issue number | 1 |
| Publication status | Published - 22 Jan 1997 |
| Externally published | Yes |
Keywords
- alpha interferon
- antibody
- beta interferon
- blood clotting factor 8
- granulocyte macrophage colony stimulating factor
- growth hormone
- insulin
- interleukin 2
- interleukin 6
- recombinant DNA
- antibody production
- antigenicity
- conference paper
- drug formulation
- human
- immunoassay
- standardization